Looking ahead, several avenues for future research can be identified. First, it is essential to conduct experimental validation of the predicted ligand-protein interactions to confirm the therapeutic potential of the identified compounds. This could involve in vitro and in vivo studies to assess the efficacy and safety of these multitarget ligands in relevant biological models of AD; also expanding the database of known active and inactive compounds within the AlzyFinder framework could further enhance the predictive power of the machine learning models. Incorporating data from recent studies and clinical trials will ensure that the platform remains up-to-date and relevant in the rapidly evolving field of AD research.